Tamoxifen use and osteoporotic fracture risk: A population-based analysis

Journal of Clinical Oncology

Volumn 26, Issue 32, 2008, Pages 5227-5232

  Cooke, Andrew L ^a   Metge, Colleen ^a   Lix, Lisa ^a   Prior, Heather J ^a   Leslie, William D ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANADA; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNICITY; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VERTEBRA FRACTURE; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; FRACTURES, BONE; HUMANS; MANITOBA; MIDDLE AGED; ODDS RATIO; OSTEOPOROSIS, POSTMENOPAUSAL; POPULATION SURVEILLANCE; RISK ASSESSMENT; RISK FACTORS; TAMOXIFEN;

EID: 55949128783     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.7123     Document Type: Article

References (40)

1. Johnell O, Kanis JA: An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726-1733, 2006
2. Cummings SR, Bates D, Black DM: Clinical use of bone densitometry: Scientific review. JAMA 288:1889-1897, 2002
3. Ramaswamy B, Shapiro CL: Osteopenia and osteoporosis in women with breast cancer. Semin Oncol 30:763-775, 2003
4. Chen Z, Maricic M, Bassford TL, et al: Fracture risk among breast cancer survivors: Results from the Women's Health Initiative Observational Study. Arch Intern Med 165:552-558, 2005
5. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652-1662, 2005
6. Powles TJ, Ashley S, Tidy A, et al: Twentyyear follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283-290, 2007
7. Cuzick J, Forbes JF, Sestak I, et al: Long-term results of tamoxifen prophylaxis for breast cancer: 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272-282, 2007
8. Veronesi U, Maisonneuve P, Rotmensz N, et al: Tamoxifen for the prevention of breast cancer: Late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99:727-737, 2007
9. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989
10. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial - Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 2:171-175, 1987
11. Rutqvist LE, Johansson H: Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 46:133-145, 2007
12. Ding H, Field TS: Bone health in postmenopausal women with early breast cancer: How protective is tamoxifen? Cancer Treat Rev 33:506-513, 2007
13. Eastell R, Hannon RA, Cuzick J, et al: Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21:1215-1223, 2006
14. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003
15. Coates AS, Keshaviah A, Thurlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007
16. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
17. Jakesz R, Jonat W, Gnant M, et al: Switching of postmenopausal women with endocrineresponsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462, 2005
18. Roos NP, Shapiro E: Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Med Care 37:JS10-JS14, 1999
19. Roos NP: Establishing a population databased policy unit. Med Care 37:JS15-JS26, 1999
20. Kozyrskyj AL, Mustard CA: Validation of an electronic, population-based prescription database. Ann Pharmacother 32:1152-1157, 1998
21. Robinson JR, Young TK, Roos LL, et al: Estimating the burden of disease: Comparing administrative data and self-reports. Med Care 35:932-947, 1997
22. Jebamani LS, Burchill CA, Martens PJ: Using data linkage to identify First Nations Manitobans: Technical, ethical, and political issues. Can J Public Health 96 Suppl 1:S28-S32, 2005
23. Starfield B, Weiner J, Mumford L, et al: Ambulatory care groups: A categorization of diagnoses for research and management. Health Serv Res 26:53-74, 1991
24. Reid RJ, Roos NP, MacWilliam L, et al: Assessing population health care need using a claims-based ACG morbidity measure: A validation analysis in the Province of Manitoba. Health Serv Res 37: 1345-1364, 2002
25. Leslie WD, Derksen S, Prior HJ, et al: The interaction of ethnicity and chronic disease as risk factors for osteoporotic fractures: A comparison in Canadian Aboriginals and non-Aboriginals. Osteoporos Int 17:1358-1368, 2006
26. van Staa TP, Leufkens HG, Cooper C: Utility of medical and drug history in fracture risk prediction among men and women. Bone 31:508-514, 2002
27. Manitoba Centre for Health Policy: Income quintiles based on the 1996 census. http://umanitoba.ca/medicine/units/mchp
28. Taylor R, Taguchi K: Tamoxifen for breast cancer chemoprevention: Low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med 3:242-247, 2005
29. Cummings SR, Duong T, Kenyon E, et al: Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287:216-220, 2002
30. Cauley JA, Gutai JP, Sandler RB, et al: The relationship of endogenous estrogen to bone density and bone area in normal postmenopausal women. Am J Epidemiol 124:752-761, 1986
31. Zhang Y, Kiel DP, Kreger BE, et al: Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336:611-617, 1997
32. Lamont EB, Lauderdale DS: Low risk of hip fracture among elderly breast cancer survivors. Ann Epidemiol 13:698-703, 2003
33. Kanis JA, McCloskey EV, Powles T, et al: A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79:1179-1181, 1999
34. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741, 2006
35. Ettinger B, Black DM, Mitlak BH, et al: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645, 1999
36. Siris ES, Harris ST, Eastell R, et al: Skeletal effects of raloxifene after 8 years: Results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20:1514-1524, 2005
37. Love RR, Barden HS, Mazess RB, et al: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154:2585-2588, 1994
38. Zidan J, Keidar Z, Basher W, et al: Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer. Med Oncol 21:117-121, 2004
39. Powles TJ, Hickish T, Kanis JA, et al: Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84, 1996
40. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 97:1262-1271, 2005